MarketCap
Facebook
X
Telegram
C4 Therapeutics EBITDA | CCCC
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA C4 Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -113 M | -118 M | -137 M | -128 M | -80.6 M | -58.8 M | -33.9 M | -15.1 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -15.1 M | -137 M | -85.6 M |
Quarterly EBITDA C4 Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -24.3 M | -26.1 M | -27.4 M | -22.8 M | -34 M | -28.1 M | -28.8 M | - | -27.9 M | -21.1 M | -31.8 M | - | -27.4 M | -37.1 M | -27.9 M | -37.8 M | -32.1 M | -26.9 M | -31.1 M | -14.9 M | -23.9 M | -21.7 M | -20.1 M | -18.5 M | -17.9 M | -10.4 M | -11.9 M | - | -8.83 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -8.83 M | -37.8 M | -24.6 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Assembly Biosciences
ASMB
|
-12 M | $ 21.33 | -2.11 % | $ 239 M |  USA |
 |
Adagene
ADAG
|
-21 M | $ 2.02 | -4.95 % | $ 119 M |  China |
 |
Benitec Biopharma
BNTC
|
-51.1 M | $ 9.31 | -5.67 % | $ 433 M | USA |
 |
Denali Therapeutics
DNLI
|
-544 M | $ 19.85 | -2.36 % | $ 3.43 B | USA |
 |
Amarin Corporation plc
AMRN
|
-47.1 M | $ 11.75 | 0.09 % | $ 4.88 B |  Irlanda |
 |
ImmuCell Corporation
ICCC
|
4.43 M | $ 10.4 | 1.76 % | $ 93.9 M | USA |
 |
Editas Medicine
EDIT
|
-155 M | $ 2.5 | -9.09 % | $ 222 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
-467 M | $ 31.77 | 1.23 % | $ 1.84 B | USA |
 |
Cue Biopharma
CUE
|
-25.6 M | $ 18.89 | -6.21 % | $ 1.79 B | USA |
 |
Equillium
EQ
|
-23.5 M | $ 1.45 | -3.33 % | $ 83.1 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
12.8 M | $ 1.6 | -14.05 % | $ 91 M | USA |
 |
Abeona Therapeutics
ABEO
|
-86.9 M | $ 2.46 | -3.35 % | $ 130 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
106 M | $ 18.13 | 9.85 % | $ 3.05 B | USA |
 |
Atossa Therapeutics
ATOS
|
-37.1 M | $ 2.21 | 3.76 % | $ 19 M | USA |
 |
Cleveland BioLabs, Inc.
CBLI
|
-2.58 M | - | -7.31 % | $ 49 M | USA |
 |
Five Prime Therapeutics, Inc.
FPRX
|
-87 M | - | - | $ 1.77 B | USA |
 |
ADC Therapeutics SA
ADCT
|
-121 M | $ 1.51 | -9.88 % | $ 192 M |  Schweiz |
 |
Harmony Biosciences Holdings
HRMY
|
232 M | $ 33.57 | -0.62 % | $ 1.93 B | USA |
 |
Ardelyx
ARDX
|
-37.9 M | $ 3.0 | 2.39 % | $ 723 M | USA |
 |
Akebia Therapeutics
AKBA
|
24.8 M | $ 0.54 | 1.8 % | $ 139 M | USA |
 |
Alector
ALEC
|
-150 M | $ 2.54 | 3.05 % | $ 262 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-103 M | $ 1.11 | -13.62 % | $ 59.6 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
451 M | $ 21.39 | 0.52 % | $ 6.7 B | USA |
 |
Phathom Pharmaceuticals
PHAT
|
-159 M | $ 5.45 | 2.16 % | $ 397 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-37.8 M | $ 3.8 | 2.15 % | $ 728 M |  Canada |
 |
Agenus
AGEN
|
-10.2 M | $ 7.02 | -1.82 % | $ 209 M | USA |
 |
AbCellera Biologics
ABCL
|
-199 M | $ 12.44 | -0.52 % | $ 3.72 B | Canada |
 |
Artelo Biosciences
ARTL
|
-11.4 M | $ 2.14 | 2.01 % | $ 405 K | USA |
|
Immatics N.V.
IMTX
|
-182 M | $ 6.42 | -0.23 % | $ 785 M |  Germany |
 |
Aptevo Therapeutics
APVO
|
-26.1 M | $ 1.08 | -4.42 % | $ 341 K | USA |
 |
Aligos Therapeutics
ALGS
|
-87.1 M | $ 2.59 | -34.43 % | $ 25.6 M | USA |
 |
Aclaris Therapeutics
ACRS
|
-75.9 M | $ 4.13 | -2.5 % | $ 506 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-41.1 M | $ 29.38 | -2.91 % | $ 4.46 B | USA |
 |
Cellectar Biosciences
CLRB
|
-22.8 M | $ 1.24 | -3.15 % | $ 3.23 M | USA |
|
Larimar Therapeutics
LRMR
|
-172 M | $ 2.68 | 5.93 % | $ 223 M | USA |
 |
Biofrontera AG
BFRA
|
-2.28 M | - | -8.24 % | $ 105 M | Germany |
 |
Pliant Therapeutics
PLRX
|
-155 M | $ 0.78 | -2.19 % | $ 47.9 M | USA |
 |
Pharming Group N.V.
PHAR
|
74 M | $ 13.02 | -1.06 % | $ 8.97 B |  Niderland |
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
-37.4 M | - | -6.97 % | $ 657 M | USA |
 |
Capricor Therapeutics
CAPR
|
-106 M | $ 8.91 | -9.54 % | $ 414 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
172 M | $ 29.06 | -1.09 % | $ 1.36 B | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
223 M | - | 1.68 % | $ 4.65 B | China |
 |
Aquestive Therapeutics
AQST
|
-70.5 M | $ 3.52 | -0.56 % | $ 376 M | USA |
 |
Jaguar Health
JAGX
|
-44 M | $ 0.44 | -0.21 % | $ 1.03 M | USA |
 |
Arvinas
ARVN
|
-116 M | $ 6.9 | 2.07 % | $ 489 M | USA |
 |
Cerus Corporation
CERS
|
-7.26 M | $ 1.95 | -6.04 % | $ 372 M | USA |
 |
Beam Therapeutics
BEAM
|
-361 M | $ 25.16 | -6.88 % | $ 2.49 B | USA |
 |
Pulmatrix
PULM
|
-1.29 M | $ 1.39 | 2.58 % | $ 5.08 B | USA |
 |
Fortress Biotech
FBIO
|
-69.8 M | $ 1.9 | -4.52 % | $ 53 M | USA |
 |
Inhibrx
INBX
|
-218 M | $ 90.63 | -1.21 % | $ 4.27 B | USA |